Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Results Conference Call May 7, 2024 5:00 PM ET
Company Participants
Kevin Balthaser - Chief Financial Officer
Neal Walker - Interim Chief Executive Officer
Joe Monahan - Chief Scientific Officer
Wally Smith - Scientific & Business Development Consultant
Conference Call Participants
Roger Song - Jefferies
Thomas Smith - Leerink Partners
Corinne Jenkins - Goldman Sachs
Julian Harrison - Big TIG
Alex Thompson - Stifel
Gavin Clark-Gartner - Evercore ISI
Operator
Good day, and thank you for standing by. Welcome to the Aclaris Therapeutics First Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Kevin Balthaser. Please go ahead.
Kevin Balthaser
Thank you. I am Kevin Balthaser, Chief Financial Officer for Aclaris. Please note that earlier today, we issued a press release highlighting our first quarter 2024 financial results and other business matters. For those of you who have not yet seen it, you will find the release posted under the Press Releases page of the Investors section of our website at www.aclaristx.com. In addition, we will be referring to a slide deck entitled ITK Portfolio, which can be found on the Investor Presentations page of the Investors section of our website and furnished as an exhibit to our Form 8-K that we filed with the SEC earlier today.
Joining me today for the call are Neal Walker, our Interim Chief Executive Officer and Joe Monahan, our Chief Scientific Officer; Wally Smith, our Scientific and Business Development Consultant will also be available for the Q&A portion of the call.
Before we begin our prepared remarks, I would
- Read more current ACRS analysis and news
- View all earnings call transcripts